← Back to screener

Altimmune, Inc. ALT

Rank #2218 · Nasdaq · $0.4B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
28.9
P/E
-4.2
P/B
2.04
ROE
-49.0%
Op. Margin
-515860.0%
Debt Ratio
8%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E -4.2x, P/B 2.04x. Ranks in the top 64% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -49.0%. Ranks in the top 94% of the universe.

Safety ★★★★★
Excellent

Debt ratio 8%. Ranks in the top 9% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 95.3% year over year. Ranks in the top 99% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.0B$-0.0B$0.0B-112.2475
2012–$-0.0B$-0.0B$0.0B–221
2013–$-0.0B$-0.0B$0.0B–91
2014–$-0.0B$-0.0B$0.0B–62
2015–$-0.0B$-0.0B$0.0B–32
2016–$-0.0B$-0.0B$0.0B–44
2017–$-0.0B$-0.0B$0.0B–14
2018$0.0B$-0.1B$-0.0B$0.0B-484.745
2019$0.0B$-0.0B$-0.0B$0.0B-414.616
2020$0.0B$-0.0B$-0.0B$0.0B-370.018
2021$0.0B$-0.1B$-0.0B$0.0B-669.542
2022$0.0B$-0.1B$-0.1B$0.2B-2197.69
2023$-0.0B$-0.1B$-0.1B$0.2B129029.411
2024$0.0B$-0.1B$-0.1B$0.2B-22518.59
2025$0.0B$-0.1B$-0.1B$0.2B-515860.08

← See the full screener